FTH
Faeth Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
32.00
▼ 0.10 (0.31%)
MARKET · —
Price
Open
33.00
Prev close
32.10
Day high
34.44
Day low
31.29
Volume
431.94K
Market cap
$826.89M
P/E (TTM)
—
52W range
7.45 – 37.90
Trailing performance
Returnvs SPY
1W
-1.05%
+0.3%
1M
+15.27%
+11.5%
3M
+82.23%
+79.1%
6M
-4.48%
-15.5%
YTD
+199.91%
+187.6%
1Y
+302.06%
+282.1%
3Y
+44.14%
-30.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$826.89M
Enterprise value$641.04M
Revenue (TTM)—
Gross profit—
EBITDA$-36.64M
Net income$-195.53M
EPS (TTM)$-60.86
Free cash flow$855.13K
Total cash$186.44M
Total debt$592.00K
Book value / share$6.70
Shares outstanding25.84M
Float18.55M
Short % of float3.21%
Dividend yield—
Beta (5Y)-0.31
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.45
PEG ratio—
Price / sales—
Price / book4.78
EV / revenue—
EV / EBITDA-17.50
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-195.26%
Return on assets-20.79%
Debt / equity0.34
Current ratio19.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$21.09M | -$30.16M | -$34.10M | -$48.59M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$21.09M | -$30.16M | -$34.10M | -$48.59M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -4.76 | -2.84 | +40.3% |
| Mar 2026 | -0.62 | -131.45 | -21,101.6% |
| Dec 2025 | -4.81 | -3.74 | +22.3% |
| Sep 2025 | -4.11 | -3.62 | +11.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.66 | 1 | $0 | 0.0% |
| Next quarter | -0.69 | 1 | $0 | 0.0% |
| Current year | -11.98 | 1 | $0 | 0.0% |
| Next year | -4.96 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$54.50
High target$60.00
Low target$46.00
Implied upside70.31%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy2 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders1.44%
Held by institutions64.43%
Institutions holding54
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+883.06K
Net buying
Buy transactions
10
956.13K shares
Sell transactions
5
73.07K shares
Net transactions
+15
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
373.13K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 1, 26 | STEPHENSON BRIAN C Chief Financial Officer |
BUY | 13.63K | $326.13K | Indirect |
| Jun 26, 26 | STEPHENSON BRIAN C Chief Financial Officer |
BUY | 15.64K | $401.27K | Indirect |
| Jun 23, 26 | STEPHENSON BRIAN C Chief Financial Officer |
BUY | 17.41K | $405.92K | Indirect |
| Jun 22, 26 | PARIKH ANAND KIRAN J.D. Chief Executive Officer |
CONVERSION | 53.47K | $62.02K | Direct |
| Jun 22, 26 | PARIKH ANAND KIRAN J.D. Chief Executive Officer |
BUY | 2.81K | $55.45K | Direct |
| Jun 15, 26 | PARIKH ANAND KIRAN J.D. Chief Executive Officer |
— | 761.43K | — | Direct |
| Jun 15, 26 | HAHN STEPHEN M Director |
— | 44.76K | — | Direct |
| Jun 1, 26 | CAMBRIAN BIOPHARMA INC Beneficial Owner of more than 10% of a Class of Security |
SELL | 25.00K | $500.54K | Direct |
| Jun 1, 26 | PEYER JAMES Beneficial Owner of more than 10% of a Class of Security |
SELL | 25.00K | $500.54K | Direct |
| Apr 7, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 17.08K | $538.11K | Indirect |
| Apr 7, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.21K | $141.36K | Indirect |
| Apr 1, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 2.74K | $86.28K | Indirect |
| Apr 1, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 12.18K | $386.31K | Indirect |
| Mar 30, 26 | MILLENNIUM MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
SELL | 3.25K | $89.39K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CAMBRIAN BIOPHARMA INC |
Beneficial Owner of more than 10% of a Class of Security | 130.14K | Sale |
HAHN STEPHEN M |
Director | 44.76K | Conversion of Exercise of derivative security |
MILLENNIUM MANAGEMENT, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
PARIKH ANAND KIRAN J.D. |
Chief Executive Officer | 817.70K | Conversion of Exercise of derivative security |
PEYER JAMES |
Beneficial Owner of more than 10% of a Class of Security | 130.14K | Sale |
STEPHENSON BRIAN C |
Chief Financial Officer | — | Purchase |
Moving averages & technicals
SMA 10
31.18
+2.62% from price
SMA 20
29.07
+10.06% from price
SMA 50
26.41
+21.16% from price
SMA 100
25.32
+26.38% from price
SMA 200
20.38
+57.02% from price
EMA 12
30.76
+4.04% from price
EMA 26
29.14
+9.80% from price
EMA 50
27.32
+17.14% from price
RSI (14)
60.6
Neutral
MACD (12,26,9)
1.61
Hist 0.35
ATR (14)
3.09
9.64% of price
Realised vol 30D
96.5%
Annualised
Bollinger upper
34.69
20, 2σ
Bollinger lower
23.46
20, 2σ
50 / 200 cross
Golden
26.41 vs 20.38
Trend bias
Above 200
+57.02%
Risk profile
Beta vs SPY
1.97
More volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
96.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-69.2%
Peak to trough
Max drawdown 5Y
-97.6%
Peak to trough
ATR 14
3.09
9.64% of price
Beta (reported)
-0.31
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Needham Initiates Faeth Therapeutics at Buy With $56 Price Target
MT Newswires · 1d ago
Faeth Therapeutics Gets US FDA Fast Track Designation for Endometrial Cancer Drug Combination
MT Newswires · 5d ago
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
Business Wire · 5d ago
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Business Wire · 8d ago
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 15d ago
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
Business Wire · 15d ago
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
Business Wire · 18d ago
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls
The Fly · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.